Drug Trial Radar · NCT04553770
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Last checked: Nov 20, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
88
Planned (sponsor's estimate)
Start
Oct 9, 2020
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Jonsson Comprehensive Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Translational Research in Oncology; Daiichi Sankyo Co., Ltd.
- First posted
- Sep 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab attaches to HER2 expressed at low levels on cancer cells in a targeted way and delivers deruxtecan to kill them. Anastrozole works by decreasing estrogen production and suppressing the growth of tumors that need estrogen to grow. This study is evaluating how effective trastuzumab deruxtecan is at treating hormone receptor positive cancer cells that have low levels of HER2 expressed on them when given alone or in combination with anastrozole.
Conditions
- Early-stage Breast Cancer
- Hormone Receptor Positive Breast Carcinoma
- Invasive Breast Cancer
- Stage II Breast Cancer
- Stage IIA Breast Cancer
- Stage IIB Breast Cancer
- Stage III Breast Cancer
Interventions
AnastrozoleDrug
Given PO
Therapeutic Conventional SurgeryProcedure
Undergo surgery
Trastuzumab DeruxtecanBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathologic complete response (pCR) rateTime frame: Baseline to surgery
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
St. Joseph Heritage Healthcare
Fullerton, California · Recruiting
Cancer Blood and Specialty Clinic
Los Alamitos, California · Recruiting
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California · Recruiting
Torrance Memorial Physician Network / Cancer Care
Torrance, California · Recruiting
PIH Health
Whittier, California · Recruiting
Orlando Health, Inc. d/b/a Orlando Health UF Health Center
Orlando, Florida · Withdrawn
Ft. Wayne Medical Oncology and Hematology, Inc.
Fort Wayne, Indiana · Withdrawn
Cancer Center of Kansas
Wichita, Kansas · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.